Limits...
High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer.

Chen Y, Xing P, Chen Y, Zou L, Zhang Y, Li F, Lu X - World J Surg Oncol (2014)

Bottom Line: Increasing evidence indicates that the TGFβ/Smad signaling pathway plays a prominent role in tumor initiation, progression, and metastasis.Correlations between p-Smad2 expression and clinicopathologic characteristics were determined by Chi-square test.The 3-year overall survival rates with low and high p-Smad2 expression in stromal fibroblasts were 53.7% and 37.7%, respectively (χ2=3.86, P=0.049).

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology & Radiotherapy, the Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou 215004, Jiangsu Province, P,R, China. luxueguan@163.com.

ABSTRACT

Background: Increasing evidence indicates that the TGFβ/Smad signaling pathway plays a prominent role in tumor initiation, progression, and metastasis. Therefore, we investigate the expression of p-Smad2 in surgical resection specimens from non-small cell lung cancer, and evaluate the prognostic significance of p-Smad2 expression in stromal fibroblasts and cancer cells for patients with clinical stage I to IIIA non-small cell lung cancer.

Methods: The immunohistochemical expression of p-Smad2 was evaluated in 78 formalin-fixed paraffin-embedded surgical resection specimens from clinical stage I to IIIA non-small cell lung cancer. Correlations between p-Smad2 expression and clinicopathologic characteristics were determined by Chi-square test. The prognostic significance of p-Smad2 expression in stromal fibroblasts and cancer cells with regard to overall survival was determined by Kaplan-Meier.

Results: There were 38.5% (30/78) and 92.3% (72/78) patients with high p-Smad2 expression in stromal fibroblasts and cancer cells, respectively. There was a positive correlation between the p-Smad2 expression level in stromal fibroblasts and the p-Smad2 expression level in cancer cells (χ2=4.176, P=0.045). No significant correlation of p-Smad2 expression in stromal fibroblasts or cancer cells with any of clinicopathologic characteristics was found. The 3-year overall survival rates with low and high p-Smad2 expression in stromal fibroblasts were 53.7% and 37.7%, respectively (χ2=3.86, P=0.049). No significant association was found between low and high p-Smad2 expression in cancer cells with respect to overall survival, respectively (χ2=0.34, P=0.562).

Conclusions: The results suggested that high p-Smad2 expression in stromal fibroblasts predicted poor survival in patients with clinical stage I to IIIA non-small cell lung cancer.

Show MeSH

Related in: MedlinePlus

Kaplan-Meier curves for patients with clinical stage I to IIIA non-small cell lung cancer (NSCLC). a. different clinical stage groups; b. different p-Smad2 expression groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4230723&req=5

Fig2: Kaplan-Meier curves for patients with clinical stage I to IIIA non-small cell lung cancer (NSCLC). a. different clinical stage groups; b. different p-Smad2 expression groups.

Mentions: The median duration of follow-up for these patients was 26 months (range, 1 to 55 months). The Kaplan-Meier plots showed that the 3-year OS rate of all patients was 47.6%. The 3-year OS rates with clinical stage I + II and IIIA were 68.0% and 32.8%, respectively (χ2 = 6.27, P = 0.012; Figure 2a). The 3-year OS rates with low and high p-Smad2 expression in stromal fibroblasts were 53.7% and 37.7%, respectively (χ2 = 3.86, P = 0.049; Figure 2b). However, no significant association was found between low and high p-Smad2 expression in cancer cells with respect to OS, respectively (χ2 = 0.34, P = 0.562).Figure 2


High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer.

Chen Y, Xing P, Chen Y, Zou L, Zhang Y, Li F, Lu X - World J Surg Oncol (2014)

Kaplan-Meier curves for patients with clinical stage I to IIIA non-small cell lung cancer (NSCLC). a. different clinical stage groups; b. different p-Smad2 expression groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4230723&req=5

Fig2: Kaplan-Meier curves for patients with clinical stage I to IIIA non-small cell lung cancer (NSCLC). a. different clinical stage groups; b. different p-Smad2 expression groups.
Mentions: The median duration of follow-up for these patients was 26 months (range, 1 to 55 months). The Kaplan-Meier plots showed that the 3-year OS rate of all patients was 47.6%. The 3-year OS rates with clinical stage I + II and IIIA were 68.0% and 32.8%, respectively (χ2 = 6.27, P = 0.012; Figure 2a). The 3-year OS rates with low and high p-Smad2 expression in stromal fibroblasts were 53.7% and 37.7%, respectively (χ2 = 3.86, P = 0.049; Figure 2b). However, no significant association was found between low and high p-Smad2 expression in cancer cells with respect to OS, respectively (χ2 = 0.34, P = 0.562).Figure 2

Bottom Line: Increasing evidence indicates that the TGFβ/Smad signaling pathway plays a prominent role in tumor initiation, progression, and metastasis.Correlations between p-Smad2 expression and clinicopathologic characteristics were determined by Chi-square test.The 3-year overall survival rates with low and high p-Smad2 expression in stromal fibroblasts were 53.7% and 37.7%, respectively (χ2=3.86, P=0.049).

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology & Radiotherapy, the Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou 215004, Jiangsu Province, P,R, China. luxueguan@163.com.

ABSTRACT

Background: Increasing evidence indicates that the TGFβ/Smad signaling pathway plays a prominent role in tumor initiation, progression, and metastasis. Therefore, we investigate the expression of p-Smad2 in surgical resection specimens from non-small cell lung cancer, and evaluate the prognostic significance of p-Smad2 expression in stromal fibroblasts and cancer cells for patients with clinical stage I to IIIA non-small cell lung cancer.

Methods: The immunohistochemical expression of p-Smad2 was evaluated in 78 formalin-fixed paraffin-embedded surgical resection specimens from clinical stage I to IIIA non-small cell lung cancer. Correlations between p-Smad2 expression and clinicopathologic characteristics were determined by Chi-square test. The prognostic significance of p-Smad2 expression in stromal fibroblasts and cancer cells with regard to overall survival was determined by Kaplan-Meier.

Results: There were 38.5% (30/78) and 92.3% (72/78) patients with high p-Smad2 expression in stromal fibroblasts and cancer cells, respectively. There was a positive correlation between the p-Smad2 expression level in stromal fibroblasts and the p-Smad2 expression level in cancer cells (χ2=4.176, P=0.045). No significant correlation of p-Smad2 expression in stromal fibroblasts or cancer cells with any of clinicopathologic characteristics was found. The 3-year overall survival rates with low and high p-Smad2 expression in stromal fibroblasts were 53.7% and 37.7%, respectively (χ2=3.86, P=0.049). No significant association was found between low and high p-Smad2 expression in cancer cells with respect to overall survival, respectively (χ2=0.34, P=0.562).

Conclusions: The results suggested that high p-Smad2 expression in stromal fibroblasts predicted poor survival in patients with clinical stage I to IIIA non-small cell lung cancer.

Show MeSH
Related in: MedlinePlus